08.22.25 -- A Case For Paying Allogeneic Cell Therapy Product Donors

Learn why cryopreservation studies are so critical and how biopharmaceutical manufacturers can more easily navigate the complexities of this process.

With each batch of cell and gene therapy product representing a wealth of lifesaving potential, this biopharma company needed the right packaging solution for its relatively new therapy applications.

Cell and gene therapy for cancer continues to advance. New data show promise, alongside discussions on safety and scalability.

Integrating biomarkers into early clinical studies is crucial to determine whether a new therapy engages its biological target, triggers the intended PD effects, and shows early signs of efficacy.

Project Optimus represents a transformative shift in oncology, advocating for a more nuanced, evidence-based approach to dose selection, prioritizing patient safety alongside treatment effectiveness.

Direct outreach to potential participants and communication with their healthcare providers is key to boosting trial awareness and participation, thereby achieving recruitment targets.